


SUPPLEMENTARY MATERIAL

Over-the-counter short-acting β_2 -agonist purchase and asthma-related health outcomes:


A post hoc analysis of the SABINA III study

Supplementary Figure 1. Percentage of patients reporting SABA OTC purchase across the participating SABINA III countries




OTC, over-the-counter; SABA, short-acting β_2 -agonist; SABINA, SABA use IN Asthma.

Supplementary Figure 2. Patients from the SABINA III study included in the analysis to determine the association of SABA prescriptions and SABA OTC purchase (1–2 vs ≥ 3 SABA prescriptions [both with and without SABA OTC purchase]) with asthma-related health outcomes




OTC, over-the-counter; SABA, short-acting β_2 -agonist; SABINA, SABA use IN Asthma.

Supplementary Figure 3. Patients from the SABINA III study included in the analysis to determine the association of SABA prescriptions and SABA OTC purchase (1–2 vs ≥ 3 SABA prescriptions [both without SABA OTC purchase]) with asthma-related health outcomes




OTC, over-the-counter; SABA, short-acting β_2 -agonist; SABINA, SABA use IN Asthma.

Supplementary Figure 4. Patients from the SABINA III study included in the analysis to determine the association of SABA prescriptions and SABA OTC purchase (1–2 vs ≥ 3 SABA prescriptions [both with ≥ 1 SABA OTC purchase]) with asthma-related health outcomes



OTC, over-the-counter; SABA, short-acting β_2 -agonist; SABINA, SABA use IN Asthma.

Supplementary Figure 5. Patients from the SABINA III study included in the analysis to determine the association of SABA prescriptions and SABA OTC purchase (1–2 SABA prescriptions [without SABA OTC purchase] vs ≥ 3 SABA prescriptions [with ≥ 1 SABA OTC purchase]) with asthma-related health outcomes



OTC, over-the-counter; SABA, short-acting β_2 -agonist; SABINA, SABA use IN Asthma.